Curi Bio, Genetox, and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay
Saved in:
| Title: | Curi Bio, Genetox, and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay |
|---|---|
| Authors: | Curi Bio |
| Source: | Business Wire (English). 02/22/2024. |
| Abstract: | Curi Bio, the industry leader in developing human stem cell-based platforms for drug discovery, today announced the signing of a Memorandum of Understanding (MOU) for scientific and strategic collaboration with Genetox and DreamCIS. Genetox, an emerging biopharmaceutical company specializing in the sale and manufacture of botulinum toxin (BoT) for cosmetic and therapeutic purposes, and DreamCIS, a leading provider of CRO services supporting clinical development and regulatory affairs, will collaborate with Curi Bio to use the company’s cutting-edge neuromuscular junction (NMJ) model as a non-animal potency assay for advancing Genetox’s BOTAONE (botulinum toxin) through US FDA approval. [ABSTRACT FROM PUBLISHER] |
| Database: | Regional Business News |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Curi Bio, the industry leader in developing human stem cell-based platforms for drug discovery, today announced the signing of a Memorandum of Understanding (MOU) for scientific and strategic collaboration with Genetox and DreamCIS. Genetox, an emerging biopharmaceutical company specializing in the sale and manufacture of botulinum toxin (BoT) for cosmetic and therapeutic purposes, and DreamCIS, a leading provider of CRO services supporting clinical development and regulatory affairs, will collaborate with Curi Bio to use the company’s cutting-edge neuromuscular junction (NMJ) model as a non-animal potency assay for advancing Genetox’s BOTAONE (botulinum toxin) through US FDA approval. [ABSTRACT FROM PUBLISHER] |
|---|
